Katie Robinson

In this Q&A, Vinod Chandran, MBBS, MD, DM, PhD, discussed a method to analyze biomarkers that may differentiate patients with psoriasis and psoriatic arthritis.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

Researchers report on the global real-world safety profile of tofacitinib in psoriatic arthritis.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.

In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.

Etanercept was effective at 6 months of follow-up and remained so at 12 months, with low rates of adverse events.

Celastrol may regulate core target proteins to alleviate the inflammatory response.

Patients with higher platelet or neutrophil counts or platelet/lymphocyte ratios and systemic immune/inflammation index scores were more resistant to conventional systemic agents.

Sustained low disease activity/remission was associated with functional and health-related quality of life improvements.

Both drugs were well tolerated and without any serious adverse events.

Patients with psoriatic arthritis had increased risks of non-melanoma skin cancer, lymphoma, and thyroid cancer compared with the general population.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission.

Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.

Secukinumab therapy was associated with inhibition of joint tenderness and swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition.

In this Q&A, Mireia Moreno, MD, discussed the findings of a study that evaluated the influence of HLA-B27 in the phenotypical expression of peripheral spondyloarthritis (pSpA), including psoriatic arthritis, which is the most well-defined pSpA.

The results imply the possibility of improving patient stratification based on both clinical and immune cellular phenotypes.

The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.

Holding methotrexate after the second COVID-19 vaccine dose is associated with similar immunogenicity and a lower risk of disease flare compared with withholding methotrexate after both vaccine doses.

In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.

Low disease activity may be the most appropriate treatment target for patients with high levels of structural damage and functional disability.

Risankizumab showed linear and time-independent pharmacokinetics in patients with active psoriatic arthritis and was comparable to those with plaque psoriasis.

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.

Serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of carotid plaque.

Results from a small study suggest that psoriatic arthritis and rheumatoid arthritis osteoclasts might retain some of their immune cell functions during differentiation.

Treatment with apremilast was associated with extended time to biologic initiation when compared with treatment with methotrexate.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of his study that examined the variables associated with achieving minimal disease activity in patients with recent-onset psoriatic arthritis.